Outcomes
ADVERSE REACTIONS, SECONDARY
The primary efficacy outcome was the suppression of EBV in the sputum measured using qPCR between baseline and week 8. EBV suppression was defined as a 90% reduction in the viral load at week 8. The primary safety outcome was the incidence of serious adverse reactions. Prespecified secondary outcomes included the change in FEV